laropiprant + rosuvastatin

laropiprant + rosuvastatin is a fixed-dose combination (FDC) therapy that was developed by AstraZeneca for the treatment of hypercholesterolemia. It consists of laropiprant, a selective antagonist of the prostaglandin D2 receptor subtype 1 (DP1), and rosuvastatin, a potent HMG-CoA reductase inhibitor (statin). The combination was designed to evaluate whether the addition of laropiprant to rosuvastatin could provide incremental lowering of low-density lipoprotein cholesterol (LDL-C) and improve other lipid parameters. Development reached Phase III clinical trials (e.g., NCT01495364), but the program was discontinued in early 2013. This decision followed the results of the HPS2-THRIVE study, which showed that a different laropiprant-containing product (Tredaptive, a combination of niacin and laropiprant) failed to reduce major adverse cardiovascular events and was associated with an increased risk of non-fatal serious adverse events.

Other names

laroprovstat/rosuvastatinlaropiprant/rosuvastatinlaroprovstat + rosuvastatinlaropiprant + rosuvastatin